ChemSpider 2D Image | (1R,12S)-5,8,14-Triazatetracyclo[10.3.1.0~2,11~.0~4,9~]hexadeca-2(11),3,5,7,9-pentaene 2,3-dihydroxysuccinate (1:1) | C17H19N3O6

(1R,12S)-5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene 2,3-dihydroxysuccinate (1:1)

  • Molecular FormulaC17H19N3O6
  • Average mass361.349 Da
  • Monoisotopic mass361.127380 Da
  • ChemSpider ID27471474

  • defined stereocentres - 2 of 2 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(1R,12S)-5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene 2,3-dihydroxysuccinate (1:1) [ACD/IUPAC Name]
2,3-Dihydroxybernsteinsäure --(1R,12S)-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaen (1:1) [German] [ACD/IUPAC Name]
6,10-Methano-6H-azepino[4,5-g]quinoxaline, 7,8,9,10-tetrahydro-, (6R,10S)-, 2,3-dihydroxybutanedioate (1:1) (salt) [ACD/Index Name]
Acide 2,3-dihydroxysuccinique - (1R,12S)-5,8,14-triazatétracyclo[10.3.1.02,11.04,9]hexadéca-2(11),3,5,7,9-pentaène (1:1) [French] [ACD/IUPAC Name]
(±)-tartaric acid; varenicline
[375815-87-5] [RN]
375815-87-5 [RN]
Toxic Solid, Organic, N.O.S. (Varenicline tartrate)
Varenicline tartrate [USAN]

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

UN2811 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Safety:

      Sold for research purposes under agreement from Pfizer Inc. Tocris Bioscience 3754

    • Bio Activity:

      Acetylcholine (Nicotinic) Receptors Tocris Bioscience 3754
      Ion Channels Tocris Bioscience 3754
      Ligand-gated Ion Channels Tocris Bioscience 3754
      Orally active, subtype-selective ?4?2 partial agonist Tocris Bioscience 3754
      Orally active, subtype-selective alpha4beta2 partial agonist Tocris Bioscience 3754
      Orally active, subtype-selective partial agonist at ?4?2 nicotinic receptors (Ki values are 0.06, 240, 322 and 3540 nM for ?4?2, ?3?4, ?7, ?1??? receptors respectively). Reduces nicotine-evoked dopamine release in vitro and decreases nicotine self-administration in vivo. Tocris Bioscience 3754
      Orally active, subtype-selective partial agonist at alpha4beta2 nicotinic receptors (Ki values are 0.06, 240, 322 and 3540 nM for alpha4beta2, alpha3beta4, alpha7, alpha1betagammadelta receptors respectively). Reduces nicotine-evoked dopamine release in vitro and decreases nicotine self-administration in vivo. Tocris Bioscience 3754

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement